Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotinib in advanced esophageal squamous cell carcinoma
NCT03888092Phase 2Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Aug 2017
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of larotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sunshine Lake Pharma. Started Aug 2017; status: completed.
02
Drugs
larotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03888092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888092.